MA50189A - Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci - Google Patents
Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ciInfo
- Publication number
- MA50189A MA50189A MA050189A MA50189A MA50189A MA 50189 A MA50189 A MA 50189A MA 050189 A MA050189 A MA 050189A MA 50189 A MA50189 A MA 50189A MA 50189 A MA50189 A MA 50189A
- Authority
- MA
- Morocco
- Prior art keywords
- abiraterone
- administering
- processes
- forming
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762562081P | 2017-09-22 | 2017-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50189A true MA50189A (fr) | 2021-05-19 |
Family
ID=65808544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050189A MA50189A (fr) | 2017-09-22 | 2018-09-20 | Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci |
Country Status (10)
Country | Link |
---|---|
US (1) | US20190091339A1 (fr) |
EP (1) | EP3684371A4 (fr) |
JP (2) | JP2020534320A (fr) |
KR (1) | KR20200064993A (fr) |
CN (1) | CN111107852A (fr) |
AU (1) | AU2018335391A1 (fr) |
CA (1) | CA3075095A1 (fr) |
IL (1) | IL273125A (fr) |
MA (1) | MA50189A (fr) |
WO (1) | WO2019060525A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113825514A (zh) * | 2019-03-18 | 2021-12-21 | 分散技术有限责任公司 | 阿比特龙-环状寡聚体药物制剂及其形成和施用方法 |
CN110141556B (zh) * | 2019-06-24 | 2021-07-13 | 李建恒 | 一种阿比特龙包合物片剂及其制备方法 |
US20210128536A1 (en) * | 2019-11-01 | 2021-05-06 | Dispersol Technologies, Llc | Weakly basic drug and ionic polymer pharmaceutical formulations and methods of formation and administration thereof |
WO2021094992A1 (fr) * | 2019-11-14 | 2021-05-20 | Suven Life Sciences Limited | Compositions pharmaceutiques amorphes d'acétate d'abiratérone |
WO2021108022A1 (fr) * | 2019-11-30 | 2021-06-03 | Dispersol Technologies, Llc | Complexes d'inclusion associant des produits pharmaceutiques et des oligomères cycliques |
KR102363026B1 (ko) * | 2019-12-26 | 2022-02-16 | 보령제약 주식회사 | 아비라테론 아세테이트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 전립선암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2990445C (fr) * | 2007-08-21 | 2020-05-05 | Board Of Regents, The University Of Texas System | Melange thermocinetique pour des applications pharmaceutiques |
US9040080B2 (en) * | 2008-10-21 | 2015-05-26 | Southwest Research Institute | Processing of heat-sensitive active agents |
BR112014001440A2 (pt) * | 2011-07-18 | 2017-02-21 | Tokai Pharmaceuticals Inc | novas composições e métodos para o tratamento de câncer de próstata |
MY175800A (en) * | 2011-11-30 | 2020-07-09 | Astrazeneca Ab | Combination treatment of cancer |
GB201207886D0 (en) * | 2012-05-04 | 2012-06-20 | Jagotec Ag | Improvements in or relating to organic compounds |
WO2014009437A1 (fr) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Stabilité d'oxydation d'acétate d'abiratérone |
TWI686212B (zh) * | 2013-03-15 | 2020-03-01 | 阿聯商太陽法瑪全球有限公司 | 醋酸阿比特龍配方 |
WO2015032873A1 (fr) * | 2013-09-06 | 2015-03-12 | Synthon B.V. | Compositions pharmaceutiques à charge élevée comprenant de l'acétate d'abiratérone |
EP3201191A1 (fr) * | 2014-10-01 | 2017-08-09 | Mylan Laboratories Ltd. | Complexe d'empagliflozine amorphe et d'une cyclodextrine |
WO2017037647A1 (fr) * | 2015-09-02 | 2017-03-09 | Leiutis Pharmaceuticals Pvt Ltd | Compositions pharmaceutiques stables d'abiratérone |
-
2018
- 2018-09-20 EP EP18858759.6A patent/EP3684371A4/fr not_active Withdrawn
- 2018-09-20 KR KR1020207008684A patent/KR20200064993A/ko not_active Application Discontinuation
- 2018-09-20 JP JP2020516620A patent/JP2020534320A/ja active Pending
- 2018-09-20 MA MA050189A patent/MA50189A/fr unknown
- 2018-09-20 CN CN201880061714.XA patent/CN111107852A/zh active Pending
- 2018-09-20 CA CA3075095A patent/CA3075095A1/fr active Pending
- 2018-09-20 WO PCT/US2018/051914 patent/WO2019060525A1/fr unknown
- 2018-09-20 US US16/136,413 patent/US20190091339A1/en not_active Abandoned
- 2018-09-20 AU AU2018335391A patent/AU2018335391A1/en active Pending
-
2020
- 2020-03-08 IL IL273125A patent/IL273125A/en unknown
-
2023
- 2023-09-28 JP JP2023167274A patent/JP2023182674A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3684371A4 (fr) | 2021-05-19 |
CN111107852A (zh) | 2020-05-05 |
EP3684371A1 (fr) | 2020-07-29 |
WO2019060525A1 (fr) | 2019-03-28 |
CA3075095A1 (fr) | 2019-03-28 |
JP2023182674A (ja) | 2023-12-26 |
AU2018335391A1 (en) | 2020-03-26 |
IL273125A (en) | 2020-04-30 |
JP2020534320A (ja) | 2020-11-26 |
KR20200064993A (ko) | 2020-06-08 |
US20190091339A1 (en) | 2019-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50189A (fr) | Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci | |
IL275704A (en) | Pharmaceutical formulation for oral administration containing cannabinoids and poloxamer | |
EA201791702A1 (ru) | Терапевтические средства на основе гликанов и связанные с ними способы | |
MA52257A (fr) | Compositions pharmaceutiques comprenant blautia et leur administration orale | |
IL258464A (en) | Pharmaceutical compositions for oral administration of peptide drugs | |
MA51617A (fr) | Mécanisme d'administration de médicament | |
SV2017005601A (es) | Formulaciones farmacéuticas que contienen tenofovir y emtricitabina | |
IL270812B1 (en) | Solid preparations for oral administration containing semaglutide and dapagliflozin and their use in medicine | |
MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
EP3400964A4 (fr) | Préparation pharmaceutique à usage oral et goût masqué contenant de la varénicline ou un sel pharmaceutiquement acceptable de celle-ci | |
MA41326A (fr) | Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation | |
MA55015A (fr) | Formulations pharmaceutiques | |
WO2016040814A3 (fr) | Polymères de bisulfure et procédés d'utilisation associés | |
IL280083A (en) | A pharmaceutical dosage form that can be administered orally and with a modified release | |
EP3881843A4 (fr) | Agent prophylactique ou thérapeutique et composition médicinale contre une maladie à médiation par l'il-31 | |
MA53099A (fr) | Formes d'ivosidénib et compositions pharmaceutiques | |
MA50394A (fr) | Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques | |
GB201811858D0 (en) | Liquid pharmaceutical composition for oral administration comprising paracetamol and codeine | |
IL286416A (en) | Pharmaceutical formulations of abiraterone-ring oligomer and methods for their preparation and administration | |
MA44859A (fr) | Pseudodimères d'oxazoline, compositions pharmaceutiques et utilisation correspondantes | |
IL285073A (en) | Concentrated liquid pharmaceutical preparations of furosemide and methods of administering these preparations | |
IL284132A (en) | A pharmaceutical compound, a method for its preparation and its use as a medicinal substance | |
PL3880171T3 (pl) | Doustny preparat farmaceutyczny zawierający ibuprofen | |
SG11202101547WA (en) | Pharmaceutical composition for oral administration | |
CY1120749T1 (el) | Φαρμακευτικες δοσολογικες μορφες |